DNA Vaccine Delivery and Improved Immunogenicity

Kevin R. Porter, Kanakatte Raviprakash

Research output: Contribution to journalReview articlepeer-review

55 Scopus citations

Abstract

The promise of DNA vaccines is as compelling today as it was more than a decade ago. Ease of manufacture, stability at ambient temperatures without the need for a cold chain and its ability to mimic natural infections and elicit appropriate immune responses makes this vaccine platform extremely attractive. Although, human clinical trials of DNA vaccines have yielded less than optimal results, the approval and licensing of a few veterinary vaccines is testimony to the proof-of-concept and the hope that licensed DNA vaccines for human use may not be too far away. Delivery and targeting of immunologically relevant cells appears to be the major hurdle in maximizing the immunogenicity of DNA vaccines. Several different approaches that are currently pursued in achieving this objective are discussed.

Original languageEnglish
Pages (from-to)129-138
Number of pages10
JournalCurrent issues in molecular biology
Volume22
DOIs
StatePublished - 2017
Externally publishedYes

Fingerprint

Dive into the research topics of 'DNA Vaccine Delivery and Improved Immunogenicity'. Together they form a unique fingerprint.

Cite this